Jennifer Taher, PhD, FCACB, is a Clinical Biochemist in the Department of Pathology & Laboratory Medicine at Mount Sinai Hospital and Assistant Professor at the University of Toronto. Throughout the pandemic she has played an active role in various COVID-19 initiatives including leading and contributing to the development several national guidance documents. She has also been at the forefront of validating SARS-CoV-2 antibody assays across multiple instrument platforms for implementation for clinical use. She is also the co-principle investigator of a a multi-hospital prospective COVID-19 research project (GENCOV) that looks at implementation of serological and molecular tools to inform COVID-19 patient management. Her research has uncovered patient risk factors for severe COVID-19 and is answering novel questions that can improve the management and outcome of critically ill patients.